ADVFN US – Market Content Editor
-
Kennedy Wilson jumps after agreeing to $10.90-a-share buyout
Kennedy Wilson (NYSE:KW) surged 9% after announcing it had reached a definitive agreement to be taken private in an all-cash deal at a substantial premium to its prior closing price. The real estate investment manager said it will be acquired for $10.90 per share in cash by a consortium led by Chairman and CEO William…
-
Krystal Biotech slips more than 2% even after Q4 earnings and revenue top estimates
Krystal Biotech Inc (NASDAQ:KRYS) on Tuesday delivered fourth-quarter results that came in ahead of Wall Street forecasts, though its shares moved lower in early trading. The stock declined 2.33% in pre-market activity despite the earnings beat. The gene therapy specialist reported adjusted earnings per share of $1.70, surpassing analyst expectations of $1.58 by $0.12. Quarterly…
-
Somnigroup International posts in-line Q4 earnings, sales trail forecasts
Somnigroup International Inc (NYSE:SGI) on Tuesday delivered fourth-quarter adjusted earnings that met analyst projections, though revenue came in below market expectations. Shares of the mattress maker declined 0.99% in pre-market trading following the release. The company reported adjusted earnings per share of $0.72 for the quarter, matching Wall Street estimates. Revenue totaled $1.87 billion, missing…
-
USA Compression Partners reports softer Q4 profit, earnings miss despite record revenue
USA Compression Partners LP (NYSE:USAC) on Tuesday posted fourth-quarter 2025 results that came in below analyst forecasts on the bottom line, even as the partnership delivered the highest quarterly revenue in its history. Shares of the natural gas compression services provider gained 1.50% in pre-market trading following the announcement. Net income for the quarter totaled…
-
Ocular Therapeutix plunges 35% despite positive wet AMD Phase 3 data
Ocular Therapeutix Inc. (NASDAQ:OCUL) shares dropped 35% on Tuesday even after the company announced favorable results from its Phase 3 superiority study of AXPAXLI in patients with wet age-related macular degeneration (wet AMD). The biotech group said AXPAXLI achieved the primary endpoint in the SOL-1 trial, showing superiority over aflibercept in preserving vision at Week…
-
General Mills slides after trimming fiscal 2026 guidance
General Mills (NYSE:GIS) shares dropped 3.6% on Tuesday morning after the packaged food company lowered its outlook for fiscal 2026, pointing to a tougher consumer backdrop. The Minneapolis-based group, whose portfolio includes brands such as Cheerios and Betty Crocker, now expects organic net sales to decline between 1.5% and 2% in fiscal 2026. That compares…
-
Shutterstock tops Q4 profit forecasts despite sharp revenue drop
Shutterstock Inc. (NYSE:SSTK) reported fourth-quarter adjusted earnings above expectations on Tuesday, even as revenue declined significantly amid continued pressure in its core content operations. Shares were little changed in pre-market trading following the release. The digital content provider delivered adjusted earnings per share of $0.67 for the quarter, ahead of the $0.51 consensus estimate. Revenue,…
-
SunCoke Energy slides more than 3% after weak Q4 results
SunCoke Energy Inc. (NYSE:SXC) posted a sizeable fourth-quarter loss on Tuesday, missing Wall Street earnings expectations despite reporting stronger-than-anticipated revenue. Shares dropped 3.38% in pre-market trading as investors reacted to the earnings shortfall and the impact of significant one-off charges. The coke producer and industrial services provider reported a net loss of $85.6 million, or…
-
Fluor drops almost 5% after Q4 earnings come in below forecasts
Fluor Corporation (NYSE:FLR) posted fourth-quarter 2025 adjusted earnings that fell short of Wall Street expectations on Tuesday, even as it advanced plans to monetize its investment in NuScale Power and continued share buybacks. Shares declined 4.84% in pre-market trading following the announcement. The company reported adjusted earnings of $0.33 per share for the quarter, missing…
-
Medtronic tops Q3 forecasts with strongest revenue growth in 10 quarters
Medtronic plc (NYSE:MDT) reported fiscal third-quarter 2026 results that exceeded analyst expectations, posting revenue of $9.0 billion. Sales rose 8.7% on a reported basis and 6.0% organically compared with the same period a year earlier. Adjusted earnings per share came in at $1.36, ahead of the $1.34 consensus estimate, while revenue also surpassed forecasts of…